PEAT Act of 2026
- Sponsor
- Rep. Rulli, Michael A. [R-OH-6]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Apr 30, 2026
Bottom line
The bill seeks to preserve the existing regulatory classification for specific biologics, particularly certain thyroid medications, by ensuring that the presence of clinically inactive proteins alone does not trigger reclassification as a biological product.
What it actually does
This bill amends the Public Health Service Act to clarify that a biologic should not be treated as a “biological product” solely because it contains a protein that is a clinically inactive component. This aims to prevent certain established medications, such as desiccated thyroid extract, from being reclassified under the stricter regulatory pathway for biological products, thereby maintaining their current regulatory status.
Proponents argue
Supporters argue that this bill is essential to prevent market disruption and ensure continued patient access to long-established and effective medications, such as desiccated thyroid extract. They contend that reclassifying these products solely due to inactive protein components would impose unnecessary and costly regulatory hurdles without a clear public health benefit, potentially leading to product shortages, increased prices, or reduced patient choice.
Opponents contend
Opponents might argue that this bill could create an undesirable loophole in the regulatory framework for biological products, potentially undermining the Food and Drug Administration's (FDA) authority to ensure the safety and efficacy of all complex biological substances. They may contend that a consistent and rigorous review process for all biologics, regardless of the clinical activity of individual protein components, is necessary to protect public health and maintain uniform quality standards.
The bill is exceptionally short and clearly written, making it very accessible for a quick and thorough understanding by any interested reader.
Section 2(a)
Prohibition on Treating Biologics as Biological Products Based on Clinically Inactive Proteins
This provision amends Section 351(i)(1) of the Public Health Service Act to explicitly state that a biologic cannot be treated as a “biological product” solely due to the presence of a protein that is a clinically inactive component within that biologic. This clarification is intended to prevent certain medications, which may contain inactive proteins, from being subjected to the more stringent regulatory pathway typically applied to biological products, thus maintaining their current regulatory status.
Supporters argue
Supporters argue that this specific provision is critical for preventing the unnecessary reclassification of established medications that have a long history of safe and effective use under existing regulatory frameworks. They contend that imposing new, more complex biological product regulations based solely on clinically inactive proteins would be an overreach that could harm patients by limiting access or increasing costs without a clear public health benefit.
Critics contend
Critics might argue that this provision could create an arbitrary exception within the FDA's comprehensive regulatory framework for biologics. They may contend that a consistent application of biological product definitions, even for inactive components, is necessary to maintain the integrity of the regulatory system and ensure that all complex substances are subject to appropriate scrutiny, regardless of their historical classification.
Tradeoffs
This provision navigates the tension between maintaining regulatory consistency for all biological substances and ensuring practical, uninterrupted patient access to established medications. It balances the desire to avoid unnecessary regulatory burdens for certain products against the principle of rigorous, uniform oversight for all complex biological components.